UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of: March, 2006
Commission File Number: 000-50393
NEUROCHEM INC.
275 Armand-Frappier Boulevard
Laval, Quebec
H7V 4A7
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40 F. Form 20-F [ ] Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes [ ] No [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): Yes
[ ] No [X]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NEUROCHEM INC.
March 30, 2006
By: /s/ David Skinner
---------------------------------------
David Skinner
General Counsel and Corporate Secretary
NEUROCHEM INC.
275 Armand-Frappier Blvd.
[NEUROCHEM(LOGO)] Laval, Quebec, Canada H7V 4A7
________________________________________________________________________________
FOR FURTHER INFORMATION, PLEASE CONTACT:
Lise Hebert, PhD Tel: (450) 680-4570
Vice President, Corporate Communications lhebert@neurochem.com
---------------------
NEUROCHEM TO PRESENT AT
CIBC WORLD MARKETS ANNUAL BIOTECHNOLOGY & SPECIALTY
PHARMACEUTICALS CONFERENCE
LAVAL, QUEBEC, MARCH 30, 2006 -- Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)
announced today that on Tuesday, April 4, 2006, Dr. Francesco Bellini, Chairman,
President and CEO, will present Neurochem's overall strategy and progress to
date at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals
Conference to be held at the Millennium Broadway Hotel, New York. The
presentation will take place at 11:30 A.M. ET, in Room 3.05. Following Dr.
Bellini's speech, the corporate presentation will be available on the Company's
website at http://www.neurochem.com/Investor.htm#Presentation.
An audio webcast of Neurochem's presentation can also be accessed at
http://www.veracast.com/webcasts/cibcwm/biotech06/99107343.cfm. This webcast
will be available for 90 days through to July 3, 2006.
ABOUT NEUROCHEM
Neurochem is focused on the development and commercialization of innovative
therapeutics to address critical unmet medical needs. Eprodisate (Fibrillex(TM))
is designated as an orphan drug, is a Fast Track product candidate and is also
part of FDA Continuous Marketing Application Pilot 1 and Pilot 2 programs. In
February 2006, the Company completed its submission of a New Drug Application
for Fibrillex(TM) that the FDA agreed, in June 2005, to file and review.
Tramiprosate (Alzhemed(TM)), for the treatment of Alzheimer's disease, is
currently in Phase III clinical trials in both North America and Europe, and
tramiprosate (Cerebril(TM)), for the prevention of Hemorrhagic Stroke caused by
Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.
TO CONTACT NEUROCHEM
For additional information on Neurochem and its drug development programs,
please call the North American toll-free number 1-877-680-4500 or visit our Web
Site at www.neurochem.com.
Certain statements contained in this news release, other than statements of fact
that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties,
known and unknown, many of which are beyond Neurochem's control. Such risks
include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical industry, changes in the regulatory
environment in the jurisdictions in which Neurochem does business, stock market
volatility, fluctuations in costs, and changes to the competitive environment
due to consolidation, as well as other risks disclosed in public filings of
Neurochem. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. The reader
should not place undue reliance, if any, on the forward-looking statements
included in this news release. These statements speak only as of the date made
and Neurochem is under no obligation and disavows any intention to update or
revise such statements as a result of any event, circumstances or otherwise.
Please see the Annual Information Form for further risk factors that might
affect the Company and its business.